GT Biopharma Inc GTBP 深 滬
等待開盤 10-08 09:30:00 美东时间
0.7517
+0.046
+6.44%
華盛通- 最 高0.80
- 今 開0.7509
- 成交量 273.25万股
- 最 低 0.65
- 昨 收 0.7062
- 總市值 267.42万
- 52周最高 4.10
- 市盈率 靜 --
- 換手率 76.81%
- 52周最低 0.55
- 委 比 -53.85%
- 總股本 355.75万
- 歷史最高 591.99
- 量 比 4.78
- 振 幅 21.24%
- 歷史最低 0.55
- 每 手 1
- 風險率 0.69%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Novel Cancer Platforms Converge as Clinical Data Reshapes Treatment Paradigms
Equity Insider News Commentary Issued on behalf of GT Biopharma, Inc. VANCOUVER, BC, Oct. 7, 2025 /PRNewswire/ -- Equity InsiderNews Commentary – Major pharmaceutical companies presenting at...
10-07 20:00
GT Biopharma to Participate in the Centurion One Capital 3rd Annual Bahamas Summit
GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company, announced that its CEO, Michael Breen, will participate in the Centurion One Capital 3rd Annual Bahamas Summit on October 28-29, 2025, in Nassau, Bahamas. The company will host one-on-one meetings during the conference. GT Biopharma focuses on developing immuno-oncology therapies using its proprietary TriKE® NK cell engager platform, licensed from the University of Minne...
10-06 13:00
GT Biopharma Alters Preferred Stockholder Rights
GT Biopharma ( ($GTBP) ) has issued an update. In September 2025, GT Biopharma‘...
09-27 04:53
GT Biopharma Waives Series L Stock Redemption Rights
GT Biopharma ( ($GTBP) ) just unveiled an announcement. In September 2025, GT B...
09-24 05:57
GT Biopharma Reports Reduced Losses Amid Ongoing Challenges
Gt Biopharma, Inc. ( ($GTBP) ) has released its Q2 earnings. Here is a breakdow...
09-05 11:51
GT Biopharma to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
GT Biopharma's Michael Breen will participate in the H.C. Wainwright Global Investment Conference on Sept 8-10, 2025 in NYC. A webcast of their presentation will be available starting Sept 5. The company continues to enroll patients in its GTBP-3650 Phase 1 trial for CD33-expressing hematologic malignancies and expects to release initial data later this year. GTB-5550 TriKE® IND submission for B7H3-positive solid tumors is on track for Q4 2025.
09-04 11:00
GT Biopharma Renews CEO Michael Breen’s Contract
An update from GT Biopharma ( ($GTBP) ) is now available. On August 26, 2025, G...
08-30 04:55
GT Biopharma Q2 EPS $(0.55) Beats $(0.68) Estimate
GT Biopharma (NASDAQ:GTBP) reported quarterly losses of $(0.55) per share which beat the analyst consensus estimate of $(0.68) by 19.12 percent. This is a 74.65 percent increase over losses of $(2.17) per share from the
08-15 04:42
GT Biopharma Reports Second Quarter 2025 Financial Results
GT Biopharma, Inc. reported that its GTB-3650 TriKE® Phase 1 trial has completed dosing for Cohort 1 and 2, treating four patients, and has advanced into Cohort 3. Initial Phase 1 data is expected in late 2025. The company anticipates submitting an IND application for GTB-5550 in Q4 2025. As of June 30, 2025, GT Biopharma had $5.3 million in cash, sufficient to fund operations into Q1 2026. The company noted a decrease in R&D and SG&A expenses, r...
08-14 20:05
GT Biopharma Initiated Dosing In Cohort 3 Of Its Phase 1 Dose Escalation Trial Of GTB-3650 For Relapsed Or Refractory CD33 Expressing Hematologic Malignancies, Plans On Releasing Initial Phase 1 Results Later In 2025 Following Completion Of Additional Dose Cohorts
The first patient in Cohort 3, the fifth patient in the trial, has completed the first week of cycle 1 following the successful safety review of Cohort 2 with no safety or tolerability issues observed.The company plans
08-11 19:14
